Dr. Levy on Molecular Drivers in NSCLC

Partner | Cancer Centers | <b>Sidney Kimmel Cancer Center at Jefferson</b>

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the identification of molecular drivers in non&shy;—small cell lung cancer (NSCLC).

Multiple actionable mutations have been identified in lung cancer, including EGFR, ALK, RET, ROS1, BRAF, HER2, MET exon 14 skipping, NTRK, and KRAS G12C. As such, there are a number of approved or investigational agents for patients with these mutations, says Levy.

Due to the growing number of targets that are emerging, all patients with advanced lung cancer should undergo comprehensive genomic profiling with next-generation sequencing, concludes Levy.